Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00464256
Status:
COMPLETED
Last Update Posted:
2010-12-10
First Post:
2007-04-20
Brief Title:
Comparison of Efficacy and Safety of Rimonabant 20mgDay Versus Placebo in Smoking Cessation
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Comparison of the Efficacy and Safety of a 20 mgDay Oral Dose of Rimonabant Versus Placebo as an Aid to Smoking Cessation - a US Randomized Double-blind 2 Arm Placebo-controlled Parallel-group Fixed Dose 12-week Study
Status:
COMPLETED
Status Verified Date:
2010-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STRATUS-META
Brief Summary:
The primary objective is to assess the efficacy a 20mgday fixed dose of rimonabant versus placebo on abstinence from tobacco use in cigarette smoker
The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period
The secondary objective is to evaluate the effects of rimonabant on craving and weight and on the clinical and biological safety and tolerability of rimonabant in a population of cigarette tobacco smokers during a 10-week treatment period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SR141716 | None | None | None |